Lung Cancer | Tumor

CURE’s lung cancer page is an extensive resource of cancer information featuring the latest lung cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on lung cancer.

CURE® Lung Cancer Heroes® Award Program Showcases 3 Individuals Who Significantly Transformed the Space

September 24th 2022

CURE®’s Lung Cancer Heroes® Award Program honors and gives thanks to those heroes who have positively affected the lives of patients with lung cancer.

FDA Grants Retevmo Full Approval for RET Fusion-Positive Lung Cancer Treatment

September 22nd 2022

The Food and Drug Administration approved Retevmo for the treatment of patients with advanced or metastatic non-small cell lung cancer with a rearranged RET gene fusion.

Diminished Sexual Health Should Not Be a Price Paid to Survive Lung Cancer

September 21st 2022

Three out of four women with lung cancer reported experiencing moderate to severe sexual dysfunction, a survey shows.

Lumakras Improves Outcomes, Quality of Life in Patients With Lung Cancer Subtype

September 14th 2022

Lumakras outperformed chemotherapy in reducing the risk of progression or death and improving quality of life for patients with KRAS G12C-mutated non-small cell lung cancer, study results showed.

FDA’s Enhertu Approval is ‘Even More Important’ for a Group of Patients With Difficult to Treat Lung Cancer, Says Expert

September 13th 2022

An expert discusses what patients need to know about the recent FDA approval of Enhertu for HER2-mutant non-small cell lung cancer, an aggressive subtype of the disease.

Cancer Made Me Feel Invisible as I Was the Sickest Girl in Every Room

September 12th 2022

When going through treatment for advanced-stage lung cancer, people would often talk to me like I was a child, or ignore me altogether and speak to my husband.

Novel Drug Will Be Evaluated for EGFR-TKI—Mutant Lung Cancer

August 31st 2022

The first patient has been treated with H002, a novel drug being investigated for non-small cell lung cancer that is resistant to a prior EGFR TKI treatment.

Novel Drug Bests Tagrisso in Heavily Pretreated Lung Cancer

August 25th 2022

More patients with pretreated non-small cell lung cancer saw their disease disappear with abivertinib compared to Tagrisso.

I Refused to Let My Stage 4 Cancer Be a Death Sentence

August 23rd 2022

When doctors told me that there was no more they could do for my stage 4 lung cancer, I refused to believe them, and wish other patients did the same.

FDA Grants Accelerated Approval to Enhertu for Subgroup of Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

August 11th 2022

The FDA’s approval of Enhertu marks the first approval of a drug for patients with HER2-mutant unresectable or metastatic non-small cell lung cancer.

FDA Grants Tabrecta a Regular Approval for Certain Patients With Lung Cancer

August 11th 2022

The FDA approved Tabrecta for patients with non-small cell lung cancer who have a mutation that led to MET exon 14 skipping.

Two-Drug Combo Bests Chemotherapy in Front-Line Lung Cancer Treatment

August 10th 2022

Imfinzi plus tremelimumab led to better overall survival outcomes compared to standard chemotherapy in patients with metastatic non-small cell lung cancer.

EGFR C797X Mutation May Lead to Tagrisso Resistance in Patients With Lung Cancer

August 9th 2022

According to real-world data, EGFR C797X mutation is deemed the leading resistance mechanism to treatment with Tagrisso in patients with non-small cell lung cancer.

Sugemalimab Demonstrates Improved Progression-Free Survival in Some Patients with Non-Small Cell Lung Cancer

August 9th 2022

Sugemalimab demonstrated safe and efficacious results when given after concurrent chemoradiation therapy or short-course chemoradiation therapy for patients with lung cancer.

Onivyde Fails to Improve Survival Over Chemotherapy in Second-Line Small Cell Lung Cancer

August 5th 2022

Treatment with Onivyde failed to best the chemotherapy topotecan in improving overall survival in patients with small cell lung cancer whose disease failed to respond to platinum-based first-line treatment, according to findings from a primary analysis of the phase 3 RESILIENT trial.

Injectable Tecentriq Is Efficacious, Reduces Treatment Time for Lung Cancer

August 2nd 2022

Subcutaneous (injectable) Tecentriq had similar movement throughout the body, while saving on treatment time compared to intravenous administration of the drug in a group of patients with non-small cell lung cancer.

5 Lung Cancer-Related Stories to Commemorate World Lung Cancer Day

August 1st 2022

In honor of World Lung Cancer Day, CURE® compiled the five most-read lung cancer-related news items from 2022 that patients may have missed.

Educated Patient® Lung Cancer Summit Looking Ahead Panel: June 25, 2022

July 29th 2022

Watch Dr. Ravi Salgia, Dr. Erminia Massarelli, Dr. Jyoti Malhotra and Daniel Saez answer questions about advancements in lung cancer during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Advancements in Advanced-Stage Non-Small Cell Lung Cancer Presentation: June 25, 2022

July 28th 2022

Watch Dr. Jyoti Malhotra, from City of Hope, discuss advancements in advanced-stage non-small cell lung cancer during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Advancements in Early-Stage Non-Small Cell Lung Cancer Presentation: June 25, 2022

July 27th 2022

Watch Dr. Erminia Massarelli, from City of Hope, discuss advancements in early-stage non-small cell lung cancer during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Advancements in Small Cell Lung Cancer Presentation: June 25, 2022

July 26th 2022

Watch Dr. Ravi Salgia, from City of Hope, discuss advancements in small cell lung cancer during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Overcoming Barriers to Receiving Biomarker Testing Panel: June 25, 2022

July 25th 2022

Watch Nikki Martin, Dr. Ying-Chun Lo and Dr. Hossein Borghaei discuss overcoming barriers to receiving biomarker testing during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Targeted Treatment Panel: June 25, 2022

July 24th 2022

Watch Elisabeth King, Dr. Edward S. Kim and Terri Conneran answer questions about targeted therapy during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Targeted Therapies Presentation: June 25, 2022

July 23rd 2022

Watch Dr. Edward S. Kim, from City of Hope, discuss targeted therapy during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Biomarker Testing Presentation: June 25, 2022

July 22nd 2022

Watch Elisabeth King, from City of Hope, discuss biomarker testing during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Basics of the Disease Panel: June 25, 2022

July 21st 2022

Watch Dr. Farhad Mazdisnian, Dr. Terence Williams and Dr. Antoinette J. Wozniak answer questions about the basics of the disease during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Radiation Advances Presentation: June 25, 2022

July 20th 2022

Watch Dr. Terrance M. Williams, from City of Hope, discuss radiation advances during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Staging Presentation: June 25, 2022

July 19th 2022

Watch Dr. Farhard Mazdisnian, from City of Hope, discuss diagnosing early, locally advanced and metastatic disease, during the CURE Educated Patient Lung Cancer Summit.

Cosela May Decrease Chemo-Related Blood Complications During Lung Cancer Treatment

July 18th 2022

Cosela tended to decrease myelosuppressive events — when the bone marrow is not working sufficiently to produce blood cells and platelets — in patients receiving chemotherapy for extensive-stage small cell lung cancer.

Study Launches to Investigate Effectiveness of Potential First-in-Class Lung Cancer Drug

July 11th 2022

The first patient was dosed in a phase 2 trial studying the efficacy of sapanisertib in patients with NRF2-mutant relapsed/refractory lung cancer.

NEXT PAGE
PREVIOUS PAGE